

## Variant: *NM\_130839.5(UBE3A):c.1310G>A (p.Arg437Gln)*

Version: 1.0

CA7435542 [↗](#)

1399221 (ClinVar) [↗](#)

**Gene:** UBE3A ([HGNC:7337](#))

**Condition:** Angelman syndrome ([MONDO:0007113](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** c8c3c298-e55d-42a1-81fc-03fb395d44fb

**Approved on:** 2025-02-28

**Published on:** 2025-03-27

### *HGVS expressions*

#### **NM\_130839.5:c.1310G>A**

NM\_130839.5(UBE3A):c.1310G>A (p.Arg437Gln)

NC\_000015.10:g.25370864C>T

CM000677.2:g.25370864C>T

NC\_000015.9:g.25616011C>T

CM000677.1:g.25616011C>T

NC\_000015.8:g.23167104C>T

NG\_009268.1:g.73118G>A

ENST00000438097.6:c.1250G>A

ENST00000625778.3:c.1250G>A

ENST00000635914.1:c.1250G>A

ENST00000637886.1:c.1310G>A

ENST00000638011.1:c.1250G>A

ENST00000638155.1:c.1250G>A

ENST00000648336.2:c.1310G>A

ENST00000649550.1:c.1250G>A

ENST00000650110.1:c.1319G>A

ENST00000675000.1:n.1985G>A

ENST00000675177.1:c.1133G>A

ENST00000675593.1:n.4006G>A

ENST00000232165.7:c.1250G>A

ENST00000397954.6:c.1319G>A

ENST00000428984.6:c.1250G>A

ENST00000438097.5:c.1250G>A

ENST00000566215.5:c.1250G>A

ENST00000614096.4:c.1310G>A

ENST00000625778.2:c.1250G>A

ENST00000630424.2:c.1250G>A

NM\_000462.3:c.1319G>A

NM\_130838.1:c.1250G>A

NM\_130839.2:c.1310G>A

NM\_000462.5:c.1319G>A

NM\_001354505.1:c.1310G>A

NM\_001354506.1:c.1250G>A

NM\_001354507.1:c.1250G>A

NM\_001354508.1:c.1250G>A

NM\_001354509.1:c.1250G>A

NM\_001354511.1:c.1250G>A  
NM\_001354512.1:c.1250G>A  
NM\_001354513.1:c.1250G>A  
NM\_001354523.1:c.1250G>A  
NM\_001354526.1:c.1250G>A  
NM\_001354538.1:c.1310G>A  
NM\_001354539.1:c.1250G>A  
NM\_001354540.1:c.1250G>A  
NM\_001354541.1:c.1250G>A  
NM\_001354542.1:c.1250G>A  
NM\_001354543.1:c.1250G>A  
NM\_001354544.1:c.1250G>A  
NM\_001354545.1:c.1310G>A  
NM\_001354546.1:c.1133G>A  
NM\_001354547.1:c.1250G>A  
NM\_001354548.1:c.1250G>A  
NM\_001354549.1:c.1250G>A  
NM\_001354550.1:c.361+4601G>A  
NM\_001354551.1:c.301+4601G>A  
NM\_130838.3:c.1250G>A  
NM\_130839.4:c.1310G>A  
NR\_146177.1:n.18393-20732C>T  
NR\_148916.1:n.1858G>A  
NM\_001354506.2:c.1250G>A  
NM\_001354507.2:c.1250G>A  
NM\_001354508.2:c.1250G>A  
NM\_001354509.2:c.1250G>A  
NM\_001354511.2:c.1250G>A  
NM\_001354512.2:c.1250G>A  
NM\_001354513.2:c.1250G>A  
NM\_001354523.2:c.1250G>A  
NM\_001354538.2:c.1310G>A  
NM\_001354539.2:c.1250G>A  
NM\_001354540.2:c.1250G>A  
NM\_001354541.2:c.1250G>A  
NM\_001354542.2:c.1250G>A  
NM\_001354543.2:c.1250G>A  
NM\_001354544.2:c.1250G>A  
NM\_001354545.2:c.1310G>A  
NM\_001354546.2:c.1133G>A  
NM\_001354547.2:c.1250G>A  
NM\_001354548.2:c.1250G>A  
NM\_001354549.2:c.1250G>A  
NM\_001354550.2:c.361+4601G>A  
NM\_001354551.2:c.301+4601G>A  
NM\_001374461.1:c.1250G>A  
NM\_130838.4:c.1250G>A  
NR\_148916.2:n.1826G>A

Uncertain Significance

PS2 PP4

Not Met criteria codes 5

PS4 BA1 PP3 PM2 BS1

Evidence Links 0

Rett and Angelman-like Disorders VCEP [↗](#)

### Criteria Specification Information





- [↗](#) **Criteria Specification:** *ClinGen Rett and Angelman-like Disorders Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for UBE3A Version 4.0.0*
- [↗](#) **Criteria Specification Approval History**
- [↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel










### ***Rett and Angelman-like Disorders VCEP***

The c.1310G>A (p.Arg437Gln) variant in the UBE3A gene has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with clinical features of Angelman syndrome and the described phenotype meets PP4 criteria (PS2, PP4; GeneDx: internal database). The p.Arg437Gln variant has been reported in 1 additional proband with a neurodevelopmental phenotype consistent with Angelman syndrome. However, PS4 cannot be applied because PM2 does not apply (PS4\_not met). The highest population minor allele frequency of the p.Arg437Gln variant in UBE3A in gnomAD v4.1 is 0.00003 in "Remaining" populations (not sufficient to meet BS1 criteria). Computational prediction analysis tools are inconclusive for this variant (REVEL gives a score of 0.329). In summary, this variant meets the criteria to be classified as a Variant of Uncertain Significance for Angelman syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Rett and Angelman-like Disorders VCEP (PS2, PP4). (UBE3A specifications version 4.0; 02/28/2025).

#### **Met criteria codes**

<b>PS2</b>	 	This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with clinical features of Angelman syndrome (PS2; GeneDx: internal database).
<b>PP4</b>	 	The p.Arg437Gln variant in UBE3A has been reported in an individual with a clinical phenotype suggestive of Angelman syndrome (GeneDx, internal data) (PP4).

#### **Not Met criteria codes**

<b>PS4</b>	 	The p.Arg437Gln variant has been reported in 2 probands with a neurodevelopmental phenotype consistent with Angelman syndrome. However, PS4 cannot be applied because PM2 does not apply (PS4_not met).
<b>BA1</b>	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PP3</b>	 	Computational prediction analysis tools are inconclusive for this variant (REVEL gives a score of 0.329).
<b>PM2</b>		No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS1</b>	 	The highest population minor allele frequency of the p.Arg437Gln variant in UBE3A in gnomAD v4.1 is 0.00003 in "Remaining" subpopulation (not sufficient to meet BS1 criteria).

Curation History 

	▼	▼
--	---	---

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.